NCT06618872Recruiting
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 27 Sept 2024
- Start date
- 3 Dec 2024
- Primary completion date
- 30 Aug 2027
- Lead sponsor
- University Hospital, Geneva
- Diseases
- Frontotemporal dementia, Alzheimer disease
- NCT number
- NCT06618872
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 3 Dec 2024 to the primary completion date, 30 Aug 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Enrolment in previous clinical trials for AD potentially affecting amyloid and/or tau brain load
- Ferromagnetic implants and devices (including implants or devices held in place by sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not eligible for MRI scanning.
Other illness
- The presence of psychiatric disorders, extensive white matter lesions or other stigmata of vascular dementia.
Other
- Visual and auditory acuity inadequate for neuropsychological testing.
- Enrolment in other trials or studies not compatible with \[18F\]RO948 Imaging study.
- Women of childbearing potential must not be pregnant (negative urine β-hCG on the day of imaging) or breast feeding at screening
Who the study is looking for
- Written Inform Consent to participating.
- 50 to 85 years of age
- a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments)
- availability of MRI within 6 months before screening
- prescription of a diagnostic amyloid PET
- Willing and able to comply with the requirements of the study, as judged by the investigator.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Geneva University Hospital Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
| Centre Medical Universitaire Vaudois Coordinator of this site? Confirm its status | Lausanne | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.